#world pharma market size | Explore Tumblr posts and blogs

mariacallous · 2 years ago

Text

A strange thing happened in the eurozone economy at the end of last year. Despite widespread forecasts that the common currency area would plunge into recession and register negative growth in the last quarter of 2022, it managed to eke out a small gain of 0.1 percent. What is remarkable is not that Europe beat expectations, but that it was one small country—Ireland—whose surging economy single-handedly prevented the eurozone from slipping into the red.

Almost unbelievably, little Ireland, with a population of only 5 million, now has the economic scale to shift the growth statistics of the entire eurozone and its 343 million inhabitants. In 2022, Irish GDP growth of 12.2 percent compared to 3.5 percent in the eurozone as a whole. In absolute numbers, only Germany, France, and Italy contributed more than Ireland to eurozone GDP growth in 2021 and 2022. Ireland’s economic boom has enabled the country’s government to post a budget surplus of 1.6 percent of GDP, even as eurozone countries struggled with an average deficit of more than 3 percent.

Honestly, who wouldn’t want this luck of the Irish?

Look closely, however, and Ireland’s so-called economic miracle looks more than a little odd. The country’s growth is simultaneously both real and artificial. Much of it is driven by a handful of U.S. multinationals, which continue to route global sales and profits through their Irish operations to take advantage of Dublin’s lower business taxes. Although difficult and complex to calculate, Apple’s shifting of intellectual property assets to Ireland is estimated to have contributed half of Ireland’s miraculous 26 percent GDP growth in 2016. That bizarre fact inspired New York Times columnist Paul Krugman to ridicule Ireland’s “leprechaun economics”—and the Irish statistics office to move away from using GDP as a measure of economic growth.

Yet the surge of U.S. investment in Ireland is also real. In particular, Ireland’s role as a pharmaceuticals manufacturing hub dramatically increased during the COVID-19 pandemic. Nine out of the world’s top 10 drug companies have significant production facilities in Ireland. The U.S. State Department thinks the corporate build-out in Ireland will continue, given Ireland’s status as the only remaining English-speaking European Union country following Britain’s departure. That makes it easy for international companies to operate and enjoy barrier-free access to the EU’s single market.

It’s hard to exaggerate Ireland’s dependence on U.S. tech and pharma companies for investment and taxes. Corporate tax receipts are now the second-largest source of tax revenue (after income tax) for the Irish state: 27 percent of all tax income in 2022. The average was just 9 percent in the 38 member countries of the Organisation for Economic Co-operation and Development (OECD) in 2020, the last year for which data is available. This, in turn, is fueling an unprecedented torrent of tax income for the Irish government. Corporate tax revenues were up nearly 50 percent in 2022 alone.

Just 10 multinationals—all of them U.S.-based tech and pharmaceutical companies—now pay nearly 60 percent of Ireland’s corporate tax. Directly and indirectly, U.S. multinationals employ more than 375,000 people in Ireland, approximately 15 percent of the country’s labor force. Driven by investment from the United States, foreign multinationals now account for 53 percent of all payroll taxes paid by corporate employers.

Driven by the windfall in corporate tax receipts, the Irish government’s budget surplus is expected to swell further, to 10 billion euros in 2023 and 16 billion euros in 2024. Relative to the size of the economy, this would be equivalent to a U.S. budget surplus of more than 1 trillion dollars in 2024.

The problem for Ireland is that this singular dependence exposes the country to growing risks. Take the tech sector: As multinationals like Google, Microsoft, Meta, and Amazon see their profits shrink and slash jobs worldwide, it will not only hurt the Irish economy, but deprive Dublin of tax income as well.

What’s more, the threat to Ireland’s stability from its overdependence on U.S. companies is about to be multiplied. In 2021, nearly 140 tax jurisdictions, including Ireland, agreed to a major reform of how multinationals companies will be taxed in the future. Pillar 2 of these reforms—a minimum corporate tax rate of 15 percent for large companies—is already coming into effect. In 2024, Ireland’s corporate tax rate is due to increase to 15 percent from its current level of 12.5 percent, reducing its attractiveness as a tax haven compared to other countries. The United States also approved the minimum tax plan in August 2022, despite significant private sector and political opposition.

However, it is Pillar 1 of the OECD’s reforms that will dramatically erode Ireland’s future income from corporate taxes. This reform will reallocate a share of company profits to where sales (or users) are actually located. Previously, tax liability was calculated on where the company or its subsidiary was legally based, no matter how many profits it rerouted from other parts of the world for tax-avoiding purposes. For Ireland, the consequences are obvious: U.S. multinationals operating in the EU will be forced to divide some of their sales by member state, thus significantly reducing the amount of sales and profits that can be “booked” through Ireland. This reform is due to come into force in 2024. The end of Ireland’s windfall is therefore only a matter of time.

The Irish Department of Finance estimated in January that around half of Ireland’s corporate tax receipts—$10 billion—are “transitionary” and will be lost as the new tax rules are implemented. That translates to more than 10 percent of total government spending in 2022—more than the entire Irish education budget. This is putting the Irish government on the precipice of another financial disaster, little more than a decade after it had to be bailed out of impending bankruptcy by the European Commission, European Central Bank, and the International Monetary Fund. That disaster left Ireland with one of the highest per capita public debt levels in the world.

Regardless of the impending financial train wreck, however, Dublin is unlikely to wake up from its American dream anytime soon. Diversifying its economy and revenue sources away from U.S. multinationals would require Ireland to shift its economic and geopolitical orientation, downgrade (in Dublin’s eyes) its deep relationship with the United States, and seek greater integration into the EU economy and its myriad rules.

That’s because Ireland’s dependence on U.S. multinationals is just another expression of the country’s affinity with the United States—the “shared heritage” referenced by U.S. presidents from John F. Kennedy to Ronald Reagan to Joe Biden. These ties to the United States long precede Dublin’s embrace of European integration and make it unlikely that Ireland will ever have the same intensity of economic, cultural, and other ties to France, Germany, or the rest of the EU.

The approaching economic and fiscal train wreck resulting from the new tax rules requires a fundamental change of mindset from Irish policymakers. Squaring the circle—holding on to its deep U.S. ties while integrating more closely with the EU to diversify its economy—means Dublin must give a little (and lose a little) to both sides. Yet Ireland’s ability to navigate this conundrum is doubtful. Even though the coming changes have been plain for all to see, Dublin’s current Trade and Investment Strategy does not contain any concrete policies to mitigate the overdependence on U.S. investment flows. Although the document acknowledges that EU market opportunities are underutilized, it again recognizes the importance “markets such as the UK and the US, which offer familiarity with language and culture.”

If there is no short-term solution to Ireland’s financial vulnerabilities, a few longer-term needs stand out. Dublin should ensure that its current budget surplus is invested wisely to help diversify its drivers of growth. One such driver would be significant increases in public investment in housing and public transport infrastructure to bring the country closer to Western European standards. Ireland’s tax base should be widened to allow for a wider distribution of income sources. For example, In 2021, Ireland gained just 5 percent of its tax receipts from property taxes, compared to more than 11 percent in both Britain and the United States.

Most importantly, Ireland must deepen its trading relationships outside the English-speaking world. Notwithstanding the country’s 50-year membership of the EU, a dearth of foreign language teaching has created a monolingual business culture, which priorities existing links with the United States over the development of new markets, both within and outside the EU. This needs to change if Ireland is to build a sustainable economic model.

Biden—whose family, like so many in the United States, has Irish roots—said in 2021 that “everything between Ireland and the United States runs deep.” This is Ireland’s economic reality today. As the corporate tax boom ebbs, Ireland should ensure that its American dream doesn’t become a recurring economic and financial nightmare.

2 notes · View notes

newristics · 8 hours ago

Text

How Patient Centricity is Changing the Pharmaceutical World

There is one word in the rapidly changing pharma world that is turning business on health care on its head: patient centricity. It's the patient focus that companies improve outcomes with and boost patient satisfaction. Transformation brings old pharma ways to more personal, empathetic, and effective approaches.

What is patient-centricity in pharma?

Patient centricity in pharma is the design of products, services, and processes based on what matters most to patients: better communication, faster treatments, and fewer side effects. In this sense, by listening to patients' voices, pharmaceutical companies are creating trust and loyalty in a very competitive market.

Main ways in which patient centricity is reshaping the pharma industry:

1. Enhanced drug development

The pharma companies have also begun including the patients during drug development. Adding real-time, real-life inputs to it allows them to craft drugs that would be highly responsive and attuned to each user's requirements. Consequently, the companies get:

Low clinical dropout rates

Optimized efficacy levels of treatment

Prompt regulatory approval rates

2. Customized Treatment Plans

The pharma industry is constructing customized treatment options. It does not believe in the one-size-fits-all approach; instead, companies analyze patient data to offer the following:

Personalized treatments

Enhanced drug adherence

Better quality of life

3. Improved Communication with the Patient

Patients want to be an integral part of their health journey, which has led to a growing focus on patient centricity in pharma. Pharma companies are becoming more responsive by adopting better communication strategies to ensure that patients are fully aware of their conditions and possible treatment options. They achieve this through

Transparent information sharing

Clear healthcare advice

Digital technologies in patient engagement

Technology and Patient Centricity

The advancement of technology is contributing much to pharma for the purpose of patient-centricity. Tools such as AI, telemedicine, and health apps help create real-time feedback on patients and track their monitoring. These innovations will make quick changes in the needs of patients for pharma companies.

Benefits of Patient Centricity for Pharma Companies

Enhanced Patient Engagement: Patients get a sense of value and involvement through their treatments.

Better Clinical Outcomes: Personalized care leads to more effective treatment.

Strong Brand Trust: When companies are inclined towards patients, the relationship would be better.

Conclusion

Patient centricity in pharma is no longer a trend but rather an imperative in the modern pharmaceutical landscape. Companies like Newristics are leading the charge by recognizing the importance of putting patients at the forefront of their strategies. The more companies embrace this approach, the more the industry will see advancements in drug development, treatment personalization, and patient engagement. By adopting a patient-centric model, Newristics is driving innovation and promoting better health outcomes, ultimately revolutionizing the pharmaceutical industry.

0 notes

dbmrmark · 6 days ago

Text

Primary Biliary Cirrhosis Market Growth Drivers: Share, Value, Size, Analysis , Industry Overview and Forecast to 2029

"Primary Biliary Cirrhosis Market Size And Forecast by 2029

The report further examines the innovative strategies adopted by Primary Biliary Cirrhosis Market these top players, such as embracing cutting-edge technologies, prioritizing customer-centric approaches, and optimizing operational efficiency. By analyzing case studies and real-world applications, the study demonstrates how these companies have adapted to changing market demands and regulatory landscapes. Their ability to innovate and respond to emerging challenges underscores their importance in shaping the trajectory of the Primary Biliary Cirrhosis Market.

Data Bridge Market Research analyses a growth rate in the global primary biliary cirrhosis market in the forecast period 2022-2029.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-biliary-cirrhosis-market

Nucleus is a secure, cloud-based platform designed to streamline data transfer and management for businesses. Its intuitive interface offers practice administrators and financial managers advanced filtering options, enhancing operational efficiency. By integrating various data sources, Nucleus enables effective prioritization of critical exposures, incorporating business context and threat intelligence to bolster security measures. Additionally, Nucleus supports seamless collaboration among multiple users across different applications, fostering rapid iteration and teamwork. Its deployment flexibility allows installation on-premises or via preferred cloud service providers, ensuring scalability and adaptability to meet diverse organizational needs.

Get More Detail: https://www.databridgemarketresearch.com/nucleus/global-primary-biliary-cirrhosis-market

Which are the top companies operating in the Primary Biliary Cirrhosis Market?

The Top 10 Companies in Primary Biliary Cirrhosis Market are prominent leaders known for their strong influence and significant market share. These include well-established companies which have built a reputation for their high-quality products and services. These companies are recognized for their innovation, customer satisfaction, and ability to adapt to market trends, playing a key role in shaping the growth and direction of the Primary Biliary Cirrhosis Market.

**Segments**

- By Treatment Type: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Bile Acid Binding Resins, Corticosteroids, Immunomodulatory Agents, Others. - By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others. - By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Primary biliary cirrhosis (PBC) is a chronic, autoimmune liver disease that affects the bile ducts in the liver. The global primary biliary cirrhosis market is segmented based on treatment type, end user, and distribution channel. In terms of treatment type, the market is categorized into Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Bile Acid Binding Resins, Corticosteroids, Immunomodulatory Agents, and Others. UDCA remains the primary treatment choice for PBC due to its effectiveness in managing symptoms and slowing disease progression. However, emerging therapies like OCA are gaining traction for patients who do not respond adequately to UDCA. Regarding end users, the market serves hospitals, specialty clinics, ambulatory surgical centers, and others. Hospitals are a key end user due to the availability of specialized healthcare professionals and advanced treatment options. Distribution channels for PBC drugs include hospital pharmacies, retail pharmacies, and online pharmacies.

**Market Players**

Several prominent players operate in the global primary biliary cirrhosis market, offering a range of treatment options and contributing to market growth. Companies such as Intercept Pharmaceuticals,The global primary biliary cirrhosis market is witnessing significant growth due to the rising prevalence of PBC worldwide. The market segmentation based on treatment type provides insights into the variety of options available for managing PBC. Ursodeoxycholic Acid (UDCA) remains the cornerstone of treatment for PBC, known for its efficacy in symptom management and disease progression. However, the emergence of Obeticholic Acid (OCA) as an alternative therapy is gaining prominence, particularly for patients who do not respond well to UDCA. Additionally, fibrates, bile acid binding resins, corticosteroids, immunomodulatory agents, and other treatment options offer a comprehensive approach to addressing PBC.

In terms of end users, hospitals play a crucial role in the primary biliary cirrhosis market due to the specialized care required for managing the disease. Specialty clinics and ambulatory surgical centers also contribute significantly to patient care and treatment accessibility. The distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, further facilitate the availability of PBC medications to patients worldwide. The accessibility and convenience offered by online pharmacies are becoming increasingly popular among patients seeking continuous treatment and medication refills.

Market players such as Intercept Pharmaceuticals, GlaxoSmithKline plc, Dr. Falk Pharma UK Ltd., CymaBay Therapeutics, Inc., and Genfit are at the forefront of developing innovative treatment options for PBC. These companies invest heavily in research and development to introduce novel therapies that enhance patient outcomes and quality of life. Collaborations, partnerships, and acquisitions are common strategies adopted by market players to expand their product portfolios and geographical presence in the primary biliary cirrhosis market.

Moreover, regulatory approvals, clinical trials, and product launches are key factors driving market growth and competitiveness among players. Companies like DURECT CORPORATION, Shenzhen Wan He Pharmaceutical Co., Ltd., Teijin Pharma Limited, NATCO Pharma Limited, and Zydus Cadila are also making significant contributions to**Market Players**

- Intercept Pharmaceuticals, Inc. - GlaxoSmithKline plc - Dr. Falk Pharma UK Ltd. - CymaBay Therapeutics, Inc. - Genfit - DURECT CORPORATION - Shenzhen Wan He Pharmaceutical Co., Ltd. - Teijin Pharma Limited - NATCO Pharma Limited - Zydus Cadila - F. Hoffmann-La Roche Ltd. (Switzerland) - Mylan N.V. (U.S.) - Pfizer Inc. (U.S.) - Novartis AG (Switzerland) - AstraZeneca (U.K.) - Johnson & Johnson Private Limited (U.S.) - Sun Pharmaceutical Industries Ltd. (India) - Bristol-Myers Squibb Company (U.S.) - Lilly (U.S.) - Amgen Inc. (U.S.) - Glenmark Pharmaceuticals Inc (India) - Amneal Pharmaceuticals LLC. (U.K.) - Intercept Pharmaceuticals, Inc (U.K.) - Emcure Pharmaceuticals Limited(India) - Takeda Pharmaceutical Company Limited (Japan) - Teva Pharmaceutical Industries Ltd (Israel)

The global primary biliary cirrhosis market is witnessing substantial growth, driven by the increasing prevalence of PBC on a global scale. The segmentation of the market based on treatment types reveals a diverse range of options available for managing PBC, with Ursodeoxycholic Acid (UDCA) being the primary choice for its effectiveness in symptom control and

Explore Further Details about This Research Primary Biliary Cirrhosis Market Report https://www.databridgemarketresearch.com/reports/global-primary-biliary-cirrhosis-market

Key Insights from the Global Primary Biliary Cirrhosis Market :

Comprehensive Market Overview: The Primary Biliary Cirrhosis Market is witnessing rapid growth, fueled by innovation and an increasing shift towards digital solutions.

Industry Trends and Projections: The market is forecasted to grow at a CAGR of X%, with trends such as automation and sustainability gaining momentum.

Emerging Opportunities: Growing demand for personalized and green technologies offers emerging business opportunities for new entrants.

Focus on R&D: Companies are heavily investing in research and development to create next-generation solutions and maintain competitive edges.

Leading Player Profiles: Dominant players the market with their advanced offerings and strategic expansions.

Market Composition: The market is a mix of established industry giants and innovative startups, fostering competition and rapid innovation.

Revenue Growth: Consistent revenue growth is driven by rising consumer demand, technological advancements, and new product introductions.

Commercial Opportunities: Expanding into untapped regions and investing in emerging technologies presents substantial commercial opportunities for businesses.

Get More Reports:

HER2 Inhibitors Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2028 Coatings Raw Materials Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2028 Embolization Particle Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032 Multi-Cuvette Spectrophotometer for Analytical Chemistry Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2028 Middle East and Africa Vanilla Beans and Extract Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2028 Extruded Acrylic Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2028 Data Centre Liquid Cooling Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2028 Biotech Ingredient Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2029 Viral Vectors-Based Gene Therapy for Non-Human Primates Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032 Programmatic Display Advertising Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2029 North America Denim Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031 Zero-Waste Shampoo Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Data Bridge Market Research:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 975

Email:- [email protected]"

0 notes

dutchpharma · 9 days ago

Text

Exploring the Impact of Dutch Pharma on Healthcare

The Dutch pharmaceutical industry has long been recognized for its significant contributions to global healthcare. Known for its innovation, research, and development, Dutch pharma plays a pivotal role in shaping the future of medical treatments and healthcare systems worldwide. This article delves into the key ways in which Dutch pharma influences healthcare, from drug development to global accessibility.

The Strength of Dutch Pharma in Drug Development

The Netherlands is home to some of the world’s most prominent pharmaceutical companies, such as Royal DSM and Janssen Pharmaceuticals. These companies invest heavily in research and development (R&D), focusing on groundbreaking treatments in various therapeutic areas. The strength of the Dutch pharma industry lies in its ability to rapidly develop new medications and therapies, driven by its robust clinical trial networks and cutting-edge technology.

In particular, Dutch companies have excelled in areas like oncology, immunology, and rare diseases. Their commitment to developing new and innovative treatments has led to the discovery of several life-saving drugs that have transformed patient outcomes worldwide. These breakthroughs are the result of collaborative efforts between industry leaders, academic institutions, and healthcare professionals.

Dutch Pharma’s Contribution to Global Healthcare

Dutch pharma extends its impact beyond national borders by supplying high-quality medicines to international markets. The Netherlands is a key player in the European pharmaceutical sector, with many of its drugs being distributed globally. Dutch pharmaceutical companies are particularly renowned for their commitment to ensuring the availability of medicines in underserved markets, particularly in developing regions dutch pharma.

The Dutch government and pharmaceutical organizations have forged partnerships with global health initiatives to improve access to essential medications. Programs like the Medicines Patent Pool and initiatives from the World Health Organization (WHO) have been supported by Dutch pharma companies, further demonstrating their dedication to global health equity.

Innovation in Sustainable Medicine

In addition to drug development, the Dutch pharmaceutical industry has been at the forefront of sustainable healthcare practices. Many Dutch pharma companies are dedicated to minimizing their environmental footprint by adopting green manufacturing practices and focusing on sustainable sourcing of raw materials.

Pharmaceutical companies in the Netherlands also prioritize the reduction of waste and energy consumption in the production of medicines. This forward-thinking approach to sustainability not only benefits the environment but also sets a standard for other countries and industries to follow.

The Role of Dutch Pharma in Patient-Centered Care

Another key impact of Dutch pharma on healthcare is its focus on patient-centered care. In recent years, there has been a shift towards personalized medicine, where treatments are tailored to the individual characteristics of patients. Dutch pharma companies have played an important role in advancing precision medicine, using genetic and molecular information to design treatments that target specific diseases more effectively.

By investing in diagnostics and personalized therapies, Dutch pharmaceutical companies aim to improve treatment outcomes, reduce side effects, and increase the overall efficiency of healthcare delivery. These efforts are helping to shift the focus of healthcare from a one-size-fits-all approach to a more tailored, individualized model.

Conclusion

The impact of Dutch pharma on healthcare is far-reaching and transformative. From leading innovations in drug development and global access to medications, to pushing the envelope on sustainability and patient-centered care, the Netherlands continues to make significant contributions to the global healthcare landscape. As the pharmaceutical industry evolves, the Dutch pharma sector is poised to remain at the forefront of medical advancements, improving lives and shaping the future of healthcare worldwide.

#Business

1 note · View note

global-research-report · 17 days ago

Text

Peptide Therapeutics: Market Dynamics, Challenges, and Emerging Trends

The global peptide therapeutics market size is expected to reach USD 66.41 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.1% from 2024 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights

By application, cancer held the second-largest revenue share in 2023 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment

The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class

Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production

By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth

North America held the largest share in terms of revenue in 2023 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives

Peptide Therapeutics Market Segmentation

Grand View Research has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region

Peptide Therapeutics Application Outlook (Revenue, USD Billion, 2018 - 2030)

Cancer

Metabolic Disorders

Cardiovascular Disorders

Respiratory Disorders

Gastrointestinal Disorders

Infectious Diseases

Pain

Dermatological Disorders

Neurological Disorders

Renal Disorders

Others

Peptide Therapeutics Type Outlook (Revenue, USD Billion, 2018 - 2030)

Generic

Innovative

Peptide Therapeutics Type of Manufacturers Outlook (Revenue, USD Billion, 2018 - 2030)

In-house

Outsourced

Peptide Therapeutics Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

Parenteral Route

Oral Route

Pulmonary

Mucosal

Others

Peptide Therapeutics Synthesis Technology Outlook (Revenue, USD Billion, 2018 - 2030)

Solid Phase Peptide Synthesis (SPPS)

Liquid Phase Peptide Synthesis (LPPS)

Hybrid Technology

Peptide Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

Canada

Europe

Germany

France

Spain

Italy

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

UAE

Saudi Arabia

Kuwait

List of Key Players

Eli Lilly and Company

Pfizer Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

AstraZeneca

Teva Pharmaceutical Industries Ltd.

Sanofi

Hoffmann-La Roche Ltd

Novartis AG

Novo Nordisk A/S

GlaxoSmithKline plc.

Ironwood Pharmaceuticals, Inc.

Radius Health, Inc.

Ipsen Pharma

Order a free sample PDF of the Peptide Therapeutics Market Intelligence Study, published by Grand View Research.

#Peptide Therapeutics Market

0 notes

ivareriksson78 · 27 days ago

Text

Select a suitable Specialty Chemicals Supplier in Chennai for meeting your business requirements

Specialty chemicals are very important because of the changing environments of today's industries. They are integral ingredients in manufacturing, in product formulations, and in breakthroughs across pharma, agriculture, automotive, textile, and so on. In their pursuit of objective production as well as ensuring quality standards are met, the choice of the right specialty chemical supplier has come to be the key in keeping the operations efficient while promoting sustainable growth.

Chennai is identified as the capital of Tamil Nadu. It has a vibrant industrial ambience with many different types of industries that have specialty chemical demands. The ability to source appropriate chemicals from a known supplier can affect business performance as well as profit and loss. Business size, from large manufacturing organization to small new start-up organisation, does not matter.

Role of Specialty Chemicals in Industrial World Today

Specialty chemicals are chemical products that are manufactured for specific uses in various industries. Unlike bulk chemicals, they are not manufactured in large quantities and are mostly customized to suit the needs of the clients. Specialty chemicals contribute much to making consumer goods more effective and to the lengthening of the life span of industrial machinery, thus significantly optimizing the functionality of the final product.

Examples include specialty chemicals applied in the development, formulation, and manufacturing of pharmaceuticals. Specialty chemicals are also used by the textile industry for dyes, finishes, and treatments, which give fabrics specific qualities such as water resistance or antibacterial properties. In the automotive manufacturing sector, these specialty chemicals find applications in coatings, lubricants, and polymers, making them important for aesthetic and performance factors in vehicles.

Why Chennai is an Ideal Location for Specialty Chemicals Supply

The city is often known as the "Detroit of India" because of its rapid growth in the automotive sector. It has been a production and distribution center for chemicals over the years. The city is located on the southeastern coast, which makes it easy to transport chemical products into international markets using its highly efficient port for importing and exporting. In addition to this, the infrastructure and connectivity of the city with key sectors such as petrochemicals, pharmaceuticals, and textiles make it a good location for specialty chemical suppliers.

Chennai is extremely popular in the realm of offering customized chemical solutions to businesses because of a large number of chemical manufacturers. You will find solvents in diversified options owing to the diverse supplier base in Chennai, be it distillers, additives, or performance-enhancing chemicals.

What to Expect from a Specialty Chemicals Supplier in Chennai

While choosing a specialty chemical supplier in Chennai, businesses need to consider various factors to ensure a partnership with a trustworthy and respectable supplier. Here are a few important considerations:

Chemical Quality: The quality of chemicals procured largely determines the products produced and the entire production processes. It is best to look for suppliers that offer high-quality, certified chemicals that meet industry standards and regulations.

Tailoring and Proficiency: Specialty chemicals frequently necessitate a considerable level of customization. It is essential to collaborate with a supplier capable of providing expert advice and adapting solutions to align with your particular requirements.

Prompt Provision: Interruptions in the supply of chemicals can impede production and result in considerable financial losses. It is advisable to select a supplier recognized for punctual deliveries and dependable logistics, especially when functioning within sectors characterized by stringent production timelines.

Competitive Pricing: While quality must always be the top priority, special attention needs to be given to the factor of pricing. A good supplier will be able to provide competitive structures of pricing without compromising the integrity of the chemicals supplied.

Customer Support: The supplier should have excellent customer support to address technical queries, regulatory concerns, and troubleshoot when needed.

Dealing with a reliable Specialty chemicals supplier Chennai is very important. Companies cutting across various sectors can be serviced because of the strategic geographical location, strong infrastructure and abundant sources of chemical supply emanating from Chennai. The companies may engage in the efficient activities that will lead to improved productivity and sustainable profitability. They will do this by concentrating on quality, customization as well as timely delivery of specialty chemicals.

#Specialty chemicals supplier Chennai

0 notes

medicinemanufacturing · 1 month ago

Text

WHO GMP & DCGI Compliance: Ensuring Pharmaceutical Excellence in India

India's pharmaceutical industry is a global powerhouse, renowned for its ability to produce high-quality medicines at competitive prices. At the heart of this success are stringent regulatory standards, including WHO Good Manufacturing Practices (WHO GMP) and Drug Controller General of India (DCGI) compliance. These standards ensure that pharmaceutical products meet international safety, efficacy, and quality benchmarks, positioning India as a trusted supplier in the global market.

What is WHO GMP Compliance?

WHO GMP (Good Manufacturing Practices) is a globally recognized set of standards designed to ensure that pharmaceutical products are consistently produced and controlled according to quality standards. These guidelines encompass every aspect of the manufacturing process, from raw material procurement to final packaging, and emphasize the importance of:

Hygiene and Cleanliness: Ensuring a contamination-free production environment.

Qualified Personnel: Employing skilled and trained staff.

Robust Processes: Standardized operating procedures (SOPs) for all stages of manufacturing.

Quality Control: Rigorous testing and documentation to maintain product integrity.

Traceability: Detailed records to track every batch produced.

What is DCGI Compliance?

The Drug Controller General of India (DCGI) is the regulatory authority responsible for approving and overseeing pharmaceutical products and clinical trials in India. DCGI compliance is mandatory for companies manufacturing or marketing drugs in India. Key aspects of DCGI compliance include:

Approval of New Drugs: Ensuring that new medicines undergo stringent evaluation for safety and efficacy before market entry.

Clinical Trial Regulation: Monitoring trials to protect participants and validate results.

Post-Marketing Surveillance: Tracking adverse drug reactions to maintain public safety.

Licensing and Inspection: Verifying that manufacturing facilities meet regulatory standards.

The Importance of WHO GMP & DCGI Compliance in India

Global Trust and Recognition: Compliance with WHO GMP and DCGI standards builds trust among international buyers and regulatory bodies. Indian pharmaceutical companies with these certifications can export medicines to regulated markets, including the United States, Europe, and Japan.

Patient Safety: Adherence to these standards ensures that medicines are safe, effective, and free from contaminants, safeguarding patient health.

Encouraging Innovation: The rigorous approval processes under DCGI encourage companies to invest in research and development, fostering innovation in drug discovery and manufacturing.

Sustainability and Growth: Meeting global compliance standards strengthens India's reputation as the "Pharmacy of the World," driving sustainable growth and contributing significantly to the economy.

Challenges in Maintaining Compliance

High Initial Costs: Upgrading facilities and processes to meet WHO GMP standards can be expensive, especially for small and medium-sized enterprises (SMEs).

Continuous Monitoring: Ensuring ongoing compliance requires dedicated teams and robust systems for quality control and documentation.

Regulatory Updates: Keeping pace with changing regulations at both national and international levels can be challenging.

The Road Ahead for Indian Pharma

To remain competitive in the global market, Indian pharmaceutical companies must prioritize compliance with WHO GMP and DCGI standards. Investments in advanced technologies, workforce training, and robust quality management systems are critical. Furthermore, collaboration with global regulatory bodies can streamline approval processes and foster mutual recognition agreements, expanding India's footprint in international markets.

Conclusion

WHO GMP and DCGI compliance are not just regulatory requirements but essential pillars of pharmaceutical excellence in India. They ensure the production of safe and effective medicines, bolster India’s reputation on the global stage, and drive innovation within the industry. By upholding these standards, India continues to play a vital role in enhancing global healthcare outcomes.

#who #gmp

0 notes

insightsresearch · 2 months ago

Text

Pharmaceutical Contract Manufacturing and Research Services Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview

Analysis of Pharmaceutical Contract Manufacturing and Research Services Market Size by Research Nester Reveals the Market to Register with a CAGR of ~7.5% During 2025-2037 and Reach ~USD 632.9 billion by 2037

Research Nester assesses the growth and market size of the global pharmaceutical contract manufacturing and research services market which is anticipated to account for the rising generics demand, increased pharmaceutical R&D spending, and contract manufacturing and research services investments in sophisticated manufacturing technologies.

Research Nester’s recent market research analysis on “Pharmaceutical Contract Manufacturing and Research Services Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor analysis and an overview of the global pharmaceutical contract manufacturing and research servicesmarket in terms of market segmentation by service, end user and by region.

Growing Demand for Biological Therapies to Promote Global Market Share of Pharmaceutical Contract Manufacturing and Research Services

The pharmaceutical contract manufacturing and research services business is expanding due to the expiring patents of certain drugs. While the branded pharmaceutical sector has suffered huge revenue and volume losses due to patent expiration, numerous new, less expensive generic alternatives are now entering the pharmaceutical contract manufacturing and research services marketplaces. A promising indication for the expansion of the pharmaceutical contract manufacturing and research services market over the projection period is the fact that generic companies are outsourcing their production to these services.

Some of the major growth factors and challenges that are associated with the global pharmaceutical contract manufacturing and research servicesmarket are:

Growth Drivers:

SMEs' Budgetary Restrictions

Commercial Success of Biologicals For Clinical Applications

Challenges:

The primary hindrance to the growth of this market is the presence of sizable pharmaceutical corporations with in-house medication manufacturing capabilities. These companies develop their candidate drugs, conduct internal studies, and conduct clinical trials. Many companies are steadily inclined to boost their manufacturing capacity and no longer rely on outsourced services to meet the global demand for pharmaceuticals.

Access our detailed report at: https://www.researchnester.com/reports/pharmaceutical-contract-manufacturing-and-research-services-market/6455

By service, the global pharmaceutical contract manufacturing and research servicesmarket is segmented into manufacturing and research. The manufacturing segment is to register a significant CAGR during the forecast period. The increasing demand for vaccines and biosimilars is one of the main drivers of the segment's growth. The increase in companies opting to outsource the manufacturing of pharmaceutical finished goods, clinical trial materials, and active pharmaceutical ingredients (APIs) explains the profitable growth rate.

By region, the Europe pharmaceutical contract manufacturing and research services market is expected to register rapid revenue CAGR by the end of 2037. Increased funding for pharmaceutical R&D, strong intellectual property laws, shifting demographics, and a higher danger of epidemics are a few of the causes of this expansion. Furthermore, according to the European Commission, half of the pharmaceutical imports into the world's fastest-growing markets come from Europe.

Request for customization @ https://www.researchnester.com/customized-reports-6455

This report also provides the existing competitive scenario of some of the key players of the global pharmaceutical contract manufacturing and research services market which includes company profiling of AbbVie, Recipharm AB, Baxter BioPharma, Dalton Pharma Services, Thermo Fisher Scientific Inc., Piramal Pharma Solutions, Jubilant Pharmova Limited, Samsung Biologics and others.

Request Free Sample Copy of this Report @ https://www.researchnester.com/sample-request-6455

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

0 notes

chemxpert · 3 months ago

Text

Unveiling India’s Pharma Global Market Insights | Chemxpert Database

Chemxpert Database offers an in-depth look into India's booming pharma global market size, highlighting a comprehensive list of pharmaceutical products exported from India. Explore top pharmaceutical export companies in India and understand the Paracetamol manufacturing process with detailed insights into leading paracetamol manufacturers in India. Discover how India’s paracetamol global market practices drive quality and competitiveness, positioning India as a vital player in the global pharmaceutical landscape.

#top chemical raw material manufacturers in India #top pharma raw material manufacturers in India #top listed pharma companies in India #top pharma companies in India by revenue #pharma clinical trial in India #world pharma market size

0 notes

savibangar · 2 months ago

Text

Detailed Analysis of the RWE Oncology Market Report by Meticulous Research®

Meticulous Research®, recognized for its expertise in market analysis, has published a pivotal report titled, “RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029.” This report provides an extensive overview of the real-world evidence (RWE) oncology solutions market, highlighting significant growth prospects.

The report forecasts a robust CAGR of 14.2% from 2022 to 2029, predicting the market will reach $1.65 billion by the end of this period. This growth trajectory is attributed to the escalating incidence of cancer globally, the surge in healthcare big data, a transition toward value-based care models, and an increasing focus on personalized medicine. However, the report also notes that the absence of standardized methodologies for RWE development poses a considerable challenge to market expansion.

Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5276

The RWE oncology solutions market is categorized into components, applications, and end users, with a thorough analysis provided for each segment. In 2022, the real-world datasets component is expected to dominate the market. The proliferation of medical data generated in healthcare facilities, alongside the growing reliance on outcome-focused studies, underpins the importance of this segment. Additionally, there is an increasing demand for data that informs drug safety from various stakeholders, including payers and regulators.

In terms of applications, the drug development and approvals segment is projected to lead the market. The incorporation of quality-of-life metrics and Patient-Reported Outcome Measures (PROMs) into clinical trials reflects the shift toward patient-centered approaches in oncology. RWE plays a crucial role in elucidating disease trajectories and treatment pathways, which is especially critical given the rising cancer rates. The ability to leverage real-world data can significantly enhance drug discovery processes, streamline regulatory approvals, and provide insights into the effectiveness of new oncology treatments.

Browse in Depth: https://www.meticulousresearch.com/product/rwe-oncology-market-5276

When examining end users, pharmaceutical and medical device companies are anticipated to command the largest share of the market. This dominance is driven by the essential role of RWE in cancer drug development and the ongoing need to evaluate drugs' real-world performance. As the industry moves towards a value-based care paradigm, pharmaceutical companies are increasingly utilizing RWE to glean insights into clinical practices and health outcomes, thus improving cancer care delivery.

The report also conducts a geographical analysis, providing insights into key markets across North America (including the U.S. and Canada), Asia-Pacific (featuring Japan, China, and India), Europe (comprising Germany, France, the U.K., among others), Latin America, and the Middle East & Africa. This regional focus offers a comprehensive understanding of market dynamics and growth opportunities within the RWE oncology solutions landscape as it approaches 2029.

Request for Customization Report: https://www.meticulousresearch.com/request-customization/cp_id=5276

Related Research Reports:

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis >> https://www.meticulousresearch.com/product/Real-World-Evidence-Solutions-Market-4954

Synthetic Biology Market Size, Share, Forecast, & Trends Analysis>> https://www.meticulousresearch.com/product/synthetic-biology-market-5826

Bioinformatics Market Size, Share, Forecast, & Trends Analysis >> https://www.meticulousresearch.com/product/bioinformatics-market-5731

Spatial Genomics Market >> https://www.meticulousresearch.com/product/spatial-genomics-market-5763

RWE Oncology Market >> https://www.meticulousresearch.com/product/rwe-oncology-market-5276

Negative Pressure Wound Therapy (NPWT) Market >> https://www.meticulousresearch.com/product/negative-pressure-wound-therapy-market-5535

U.S. Real-World Evidence (RWE) Solutions Market >> https://www.meticulousresearch.com/product/us-rwe-solutions-market-5243

#RWE Oncology Market

0 notes

amrutatbrc1 · 2 months ago

Text

AI-Based Clinical Trial Solution Providers Market 2024 : Industry Analysis, Trends, Segmentation, Regional Overview And Forecast 2033

The ai-based clinical trial solution providers global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

AI-Based Clinical Trial Solution Providers Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The ai-based clinical trial solution providers market size has grown exponentially in recent years. It will grow from $2 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to increased complexity in clinical trials, growing volume of clinical trial data, regulatory compliance challenges, drug discovery and development demands, personalized medicine trends.

The ai-based clinical trial solution providers market size is expected to see exponential growth in the next few years. It will grow to $5.65 billion in 2028 at a compound annual growth rate (CAGR) of 23.0%. The growth in the forecast period can be attributed to integration with real-world evidence (rwe), advancements in natural language processing (nlp), decentralized clinical trials adoption, expansion of therapeutic areas, enhanced predictive analytics. Major trends in the forecast period include collaboration with biotech and pharma companies, patient-centric approaches, predictive analytics for trial design, real-world evidence integration, blockchain for data security.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/ai-based-clinical-trial-solution-providers-global-market-report

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers - The increasing adoption of AI technology is expected to propel the growth of the AI-based clinical trial solution provider market going forward. Artificial intelligence (AI) refers to the development of computer systems or software that can perform tasks that typically require human intelligence. AI technology is being increasingly used by clinical trial solution providers to bring efficiency, accuracy, and innovation to various stages of the clinical trial lifecycle, ultimately contributing to improved patient outcomes and advancements in medical research. For instance, in May 2022, according to The International Business Machines Corporation (IBM), a US-based technology corporation, the adoption rate of AI globally increased significantly by 35%, up four points from the previous year. Further, in 2022, 13% more firms are projected to have used AI than in 2021, and around 35% of organizations reported adopting AI in their company, 42% are considering AI for adoption, and two-thirds of the companies (66%) are either presently executing or intending to utilize AI to meet their sustainability goals. Therefore, the increasing adoption of AI technology is driving the growth of the AI-based clinical trial solution provider market.

Market Trends - Major companies operating in the AI-based clinical trial solution providers market are developing innovative technological innovations in the market, such as the Saama AI-driven data platform, to accelerate clinical development and strengthen their position in the market. An AI-driven data platform is a software solution that leverages artificial intelligence (AI) and machine learning (ML) to automate and enhance various data management and analysis processes. For instance, In June 2023, Saama Technologies, Inc., a US-based software company, introduced an AI-driven data platform called Saama. An AI-driven data platform streamlines clinical trial processes by centralizing and standardizing data, offering real-time insights into trial operations, financials, and patient data. The platform utilizes AI and advanced analytics to automate tasks, enhance productivity, and provide deep insights into patient behaviors. With SaaS solutions like data hubs, operational insights, patient insights, S2S, and SDQ, Saama empowers AI-based clinical trial solution providers to optimize efficiency, accuracy, and effectiveness. Additionally, it aims to eliminate manual, resource-intensive activities and make clinical trials more efficient and effective.

The ai-based clinical trial solution providers market covered in this report is segmented –

1) By Clinical Trial Phase: Phase-I, Phase-II, Phase-III 2) By Therapeutic Application: Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Metabolic Diseases, Infectious Diseases, Other Therapeutic Applications 3) By End-user : Pharmaceutical Companies, Academia, Other End-users

Get an inside scoop of the ai-based clinical trial solution providers market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13575&type=smp

Regional Insights - North America was the largest region in the AI-based clinical trial solution providers market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ai-based clinical trial solution providers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the ai-based clinical trial solution providers market report are International Business Machines Corporation, AstraZeneca, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., BenevolentAI, Charles River Laboratories, Flatiron Health, Saama Technologies Inc., CytoReason, Median Technologies SAS, Concentro Health AI. , AiCure, LLC, DEEP LENS AI Inc., GNS Healthcare, Inc., Ardigen, Koneksa Health Inc., Unlearn.AI Inc., PathAI Inc., Deep 6 AI Inc., Intelligencia Inc., Exscientia, Prometheus Biosciences, Inc., Renalytix AI plc, BioAge Labs Inc., Mendel Health Inc

Table of Contents 1. Executive Summary 2. AI-Based Clinical Trial Solution Providers Market Report Structure 3. AI-Based Clinical Trial Solution Providers Market Trends And Strategies 4. AI-Based Clinical Trial Solution Providers Market – Macro Economic Scenario 5. AI-Based Clinical Trial Solution Providers Market Size And Growth ….. 27. AI-Based Clinical Trial Solution Providers Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

trendsofmarket · 2 months ago

Text

Analysis of Pharmaceutical Contract Manufacturing and Research Services Market Outlook and Forecasts by Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis

Request Report Sample@

Growing Demand for Biological Therapies to Promote Global Market Share of Pharmaceutical Contract Manufacturing and Research Services

Access our detailed report at:

Some of the major growth factors and challenges that are associated with the global pharmaceutical contract manufacturing and research servicesmarket are:

Growth Drivers:

SMEs' Budgetary Restrictions

Commercial Success of Biologicals For Clinical Applications

Challenges:

Request for customization @

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

#pharmaceutical-contract-manufacturing-and-research-services-market-trends #pharmaceutical-contract-manufacturing-and-research-services-market-share

0 notes

marketsndata · 2 months ago

Text

Global Gastrointestinal Drugs Market Size, Share, Growth and Forecast 2031

Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market’s growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.

Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn’s disease, among others, providing lucrative growth opportunities for the market.

The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn’s disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn’s disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn’s disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn’s disease.

Increasing Cases of Gastrointestinal Diseases Boost Market Demand

The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.

Rising Efforts of Pharma Companies Supports Market Expansion

The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.

Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company’s Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market.

Retail Pharmacies Hold Significant Market Share

The segment’s expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.

Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment’s growth.

North America Holds Major Market Share

The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn’s disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market’s demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market’s expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market’s growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn’s disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market’s demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.

Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth.

Report Scope

“Gastrointestinal Drugs Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gastrointestinal drugs market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/gastrointestinal-drugs-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: [email protected] Website: https://www.marketsandata.com

#Gastrointestinal Drugs Market #Global Market #Market Research Reports #Market News

0 notes

voizmed · 3 months ago

Text

Advantages of Solan Pharma Third-Party Manufacturing

With the growing demand for pharmaceuticals, the third-party manufacturing model has emerged as a game-changer for companies seeking efficient, cost-effective production solutions.

Solan, a picturesque town in Himachal Pradesh, India, has positioned itself as a prominent hub for third party pharma manufacturing. Known for its world-class facilities, skilled workforce, and regulatory compliance, Solan offers a unique ecosystem that has drawn companies from across the country.

Let’s explore the advantages of choosing Solan for third-party pharma manufacturing:

1. Access to WHO-GMP Certified Facilities

One of the major advantages of opting for Solan as a third-party manufacturing destination is the access to WHO-GMP (Good Manufacturing Practice) certified facilities.

Pharmaceutical companies can rest assured that Solan-based manufacturers follow international standards in production, ensuring the highest quality and safety of pharmaceutical products.

2. Cost Efficiency and Resource Savings

Setting up an in-house manufacturing unit can be a heavy financial burden, especially for small and medium-sized companies. Solan’s third-party manufacturing services offer a cost-effective solution, allowing companies to save significantly on infrastructure, machinery, and labor costs.

By outsourcing manufacturing, pharma companies can allocate more resources toward R&D, marketing, and distribution, maximizing their budget in a highly competitive market.

3. Skilled and Experienced Workforce

Solan is home to a highly skilled workforce specializing in pharmaceutical manufacturing.

With trained technicians, quality control experts, and R&D professionals, the region boasts a talent pool that has been instrumental in maintaining the high standards that Solan-based manufacturers are known for.

4. Proximity to Raw Material Suppliers

Solan’s geographic location in Himachal Pradesh, close to several raw material suppliers and allied industries, is a logistical advantage. The easy availability of high-quality raw materials reduces delays and transportation costs, enabling manufacturers to deliver on time while keeping production costs low.

5. Regulatory Compliance and Quality Assurance

Solan’s third-party manufacturers are known for their strict adherence to regulatory requirements. They comply with DCGI (Drug Controller General of India) and other regulatory body guidelines, which guarantee the quality and efficacy of the products they produce.

6. Flexibility and Scalability in Production

One of the unique advantages of 3rd party pharma manufacturing in Solan is the flexibility it offers. Pharma companies can scale up or down their production volumes based on market demand, without the long-term commitments required for in-house production.

7. Focus on Innovation and New Product Development

With manufacturing in the hands of a reliable third-party provider, companies can focus more on innovation and new product development. Solan’s manufacturing ecosystem supports a range of pharmaceutical formulations, from tablets and capsules to specialized syrups and injectables, allowing pharma companies to expand their product portfolios with ease.

Conclusion

For pharmaceutical companies seeking a trusted, efficient, and scalable manufacturing solution, Solan’s third-party pharma manufacturing services offer a compelling array of advantages.

From cost savings and high-quality standards to scalability and market expansion, Solan’s manufacturers provide a strategic option for businesses aiming to grow while maintaining product quality.

#PharmaceuticalManufacturing #ThirdPartyManufacturing #SolanPharma #PharmaOutsourcing #Solan

0 notes

latestmarketresearchnews · 3 months ago

Text

Pharmaceutical Packaging Market 2030 Top Key Players, Trends, Share, Industry Size, Segmentation

The global pharmaceutical packaging market was valued at USD 139.37 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030. This growth is largely driven by the rapid expansion of the pharmaceutical industry, which has been advancing due to scientific and technological innovations. The ongoing growth is expected to continue, especially in developing regions such as China, India, Saudi Arabia, and Brazil, where healthcare infrastructure and demand for medicines are expanding significantly.

In 2023, the United States represented the largest pharmaceutical market globally. Several factors contribute to this, including a well-established healthcare system, high per capita income, and substantial investments in research and drug development. The increasing focus on generic drugs and the improvement in healthcare services are expected to provide promising opportunities for the pharmaceutical packaging market. Notably, the 21st Century Cures Act (Cures Act), signed in 2016, is aimed at accelerating medical product development in the U.S., thus fostering innovation in the pharmaceutical industry. This legislation is anticipated to boost demand for pharmaceutical packaging by supporting the launch of new and innovative drug formulations.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

Europe’s pharmaceutical sector is one of its high-performing and technologically advanced industries, significantly contributing to the regional economy. The sector is evolving with an increased focus on developing biopharmaceutical drugs, which has grown over recent years. Many biotechnology-based drug therapies are sensitive to degradation and thus require specialized packaging, such as lyophilized or dry powder forms, to maintain stability. This demand for sophisticated packaging solutions is creating new growth opportunities for packaging manufacturers.

Pharmaceutical products are primarily available in forms such as tablets, capsules, liquids, and powders. They require various packaging solutions, including rigid bottles, stand-up pouches, flat pouches, sachets, and blister packs, each designed to meet specific needs. Packaging companies are now prioritizing features like dispensing aids, administration tools, eco-friendly materials, tamper-evident seals, and anti-counterfeiting measures to enhance product safety, accessibility, and sustainability.

End-use Segmentation Insights:

The pharma manufacturing segment was the largest end-use segment in 2023, accounting for a 49.9% market share, and is anticipated to see strong growth through to 2030. This trend is primarily due to the rising demand for medicines worldwide. According to the World Health Organization (WHO), the global population aged over 60 is expected to nearly double from 12% in 2015 to 22% by 2050, increasing the need for medicines and healthcare. The aging population requires more medical assistance, which is driving pharmaceutical production and, subsequently, the demand for pharmaceutical packaging.

To manage costs and increase efficiency, pharmaceutical companies are increasingly outsourcing packaging activities. By outsourcing, companies can avoid investing directly in packaging materials and equipment, instead working with specialized contractors who provide efficient packaging solutions. This shift is expected to fuel demand for contract manufacturing and pharmaceutical packaging equipment.

Retail pharmacies, especially in developing countries like India, China, and Brazil, are using branding on packaging materials such as polybags and paper pouches to differentiate their products. As retail penetration expands in these regions, the retail pharmacy segment is likely to see significant growth.

Institutional pharmacies, which operate within healthcare facilities like hospitals, nursing homes, and assisted living communities, are expected to grow as well. The increasing number of hospitals and healthcare facilities, along with rising healthcare expenditures, is likely to drive demand for pharmaceutical packaging in this segment. With a growing focus on healthcare accessibility and quality, the institutional pharmacy end-use sector is anticipated to contribute significantly to the overall growth of the pharmaceutical packaging market.

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

#Pharmaceutical Packaging Market Forecast #Pharmaceutical Packaging Market Overview

0 notes